Prognostic Value of Impaired Fasting Glucose for Outcomes of Patients With Stable Angina Pectoris Treated With Percutaneous Coronary Interventions

The prognostic value of the newly defined impaired fasting glucose (IFG) range (100 to 109 mg/dl) for the outcomes of patients undergoing percutaneous coronary interventions is unknown. We assessed the composite of death or myocardial infarction at 1 year of follow-up in 189 patients with IFG and 801 patients with a normal fasting glucose (<100 mg/dl), all with stable angina. The 1-year cumulative rate of death or myocardial infarction was 10.3% in the IFG group and 4.4% in the normal fasting glucose group (p = 0.002). In the multivariate model, IFG was an independent predictor of the occurrence of death or myocardial infarction (adjusted hazard ratio 2.30, 95% confidence interval 1.29 to 4.08, p = 0.005). An IFG of 100 to 109 mg/dl in patients with stable angina who undergo percutaneous coronary intervention may identify a patient subset with an increased risk of death or myocardial infarction.